| Literature DB >> 21216463 |
Sonal M Manohar1, Maggie J Rathos, Vinay Sonawane, Shalini V Rao, Kalpana S Joshi.
Abstract
P276-00 is a novel cyclin-dependent kinase inhibitor especially potent for Cdk9-T1, Cdk4-D1 and Cdk1-B. Multiple myeloma (MM) is a B-cell malignancy characterized by the accumulation of malignant plasma cells. Treatment of MM cell lines with P276-00 resulted in apoptosis that correlated with transcription inhibition and a significant decline in Mcl-1 protein levels with the appearance of cleaved PARP in these cells. In vivo studies of P276-00 confirmed antitumor activity in RPMI-8226 xenograft. These results suggest that P276-00 causes multiple myeloma cell death by disrupting the balance between cell survival and apoptosis through inhibition of transcription and downregulation of Mcl-1.Entities:
Mesh:
Substances:
Year: 2011 PMID: 21216463 DOI: 10.1016/j.leukres.2010.12.010
Source DB: PubMed Journal: Leuk Res ISSN: 0145-2126 Impact factor: 3.156